A Model for Providing Quality HIV Ambulatory Care in a Rural Setting

Anndrea Rogers, BS, MT(ASCP)
Director, WVU Positive Health Clinic
Morgantown, West Virginia

Katherine Chase, RN, BSN HIV Program Coordinator, Shenandoah Valley Medical Systems Martinsburg, West Virginia

Jeannette Southerly, RN, BSN, ACRN WV LPS, Pennsylvania Mid-Atlantic AIDS Education and Training Center Morgantown, West Virginia



Three Areas of Focus

- 1. Background, Model explanation, How differs from traditional
- 2. Clinical care How it is done from the nurse who is doing it
- 3. Educational for providers Learning while providing care



Before We Begin...

- Audience Response System
- ■Why we are using it
- **■**How it will work
- 2 "practice" questions



What does a phobophobe fear?

- Strobe Lights
- ₹2. Fear
 - 3. Words that start with "ph"
 - 4. Paperwork

What is triskaidekaphobia?

- Fear of falling from the deck of a ship
- Fear of the number thirteen
- 3. Fear of being at risk for AIDS
- 4. Fear of dinosaurs

Your Primary Role...

- Care Provider (MD, PA, APN, RN, SW etc)
- Administrator
- 3. Consumer
- Case Manager
- 5. Educator
- 6. Other

Your Ryan White Part Affiliation...


- 1. Part A
- 2. Part B
- 3. Part C
- 4. Part D
- 5. Part F
- Combination of at least 2 above choices

Your Work Site Location...

- 1. Rural
- 2. Urban
- 3. Don't Know

Do you have a satellite clinic?

- 1. Yes
- 2. No
- 3. Not Applicable
- 4. I am a satellite clinic



Background









Robert C. Byrd Health Sciences Center of West Virginia University

- 2001 Planning / Capacity Building Grants
 - WVU 25 counties
 - SVMS 8 counties
- 2003 EIS Grant awarded to WVU for 33 counties







The "Shenandoah Model"





Comparison

	Traditional	Shenandoah
Travel required	Yes	No
Care provided by Grantee	Yes	No
Time required	> 1 full day	1 hr. per month
On site ID doc	Yes	No
Primary Care/Urgent Care available at satellite clinic site	No	Yes
Grantee Provider Hours per year	552	60
Patients hospitalized where HIV provider practices	No	Yes



Principle of QI Plan

Every patient encounter should be an opportunity to provide and measure the provision of quality HIV care.

-Arif Sarwari, MD, MSc Medical Director, WVU Positive Health Clinic




Clinical Care

- Shenandoah Community Health Center
 - Who Provides Care
 - 7 Internists
 - 2 Family Practice Physicians
 - 2 Family Nurse Practitioners
 - 1 Physician Assistant
 - 2 Pediatricians
 - 1 Pediatric Nurse Practitioner



Patient Flow



Monthly Patient Care Teleconference

- Preparation
- Documentation
- Attendance



		valley Medic	•	Dat	te:			
Pa	atient Care	Teleconferen	ce	Tin	ne:			
				Loc	cation:			
	ype of	Continuous		Fac	ilitator:	Kathy Chas	se, RN	
<u>m</u>	eeting:	Improvemen	t					
				Age	enda			
	Patient N	ame /	CD4	VL	Regimo	en Stable	Unstable	Plan
	Demogra	phics						
1.								
2.								
3.								
4.								
5.								
6.								
<u> </u>					-		1	
	cational Topics Covered: cational Topics to be discu	ussed at Management Conference:						
Pa	atient Name (N	o Shows)			Acti	on Taken		

Documentation

- Identification System
- **■**Encounter Form
- ■CAREWare and EMR



Date of Diagnosis:	Veer likely infected	Physician
Date of Diagnosis://	real likely lillected	Fetablished

<u>Risk</u> : □IDU □MSM □He	terosexua	ii Conta	ict Perinata	п пешорина	Odag Dis/11	ranst Dundeter	minea
LABS	DATE	R	ESULT	INVESTIG	ATION	DATE	RESULT
				Syphilis (yearly			
004				GC/Chlamydia			
CD4 count				Toxoplasma Ig			
(percentage)				Hep B sAg / sA			
				Hep B Core Ab			
				Hep C Ab			
NADIR CD4				If Hep C + then	DCD & Gon	otvoo	
NADIK OD4				Hep A Total Ab		Otype	
		1		PPD	/ igivi		
				Pap Smear (yea	velse)		
				Mammogram (i		4/	
<u>Viral Load</u>				Eye Exam (if C		J)	
				Dental Exam	D4 \U()		
					(voorby)		
				Lipid Screening			
Resistance Testing				Nutrition Scree	ning		
				Mental Health S	Screening		
				Partnership for	Health int.		
				HIV Education			
				Prevention and	Wellness		
				Patient Assess			
				Living Will / MP			
				CMV			
Ols/ Neoplasms/ Co	morbids			VACCINA	ATIONS	Da	te
<u> </u>	, , , , , , , , , , , , , , , , , , ,			Pneumococcal		<u> </u>	
	,			Influenza (year			
	8			Hepatitis A #1	y)		
	a			Hepatitis A #1			
	10						
j	11			Hepatitis B #1			
All	12	1. 1-	_	Hepatitis B #2			
Allergies / Adverse	KX prior	to AR		Hepatitis B #3			
				Tetanus/Diphth	eria (q 10yr)	
				H1N1			
			04 - 4				
	_	_	<u>Start</u>	<u> </u>		_	
042 Medications	Dose/	Freq	<u>Date</u>	Stop D	<u>ate</u>	Reason	
Dhawaa A		Data	Deta	Det-	Dot:	Campan	
Pharmacy Assess		<u>Date</u>	<u>Date</u>	<u>Date</u>	<u>Date</u>	Comments	
a. Adherence Coun							
b. Quantitative Ass	essmen	t					
Medications for	Í						
Prophylaxis	Dose/	Freq	Start Date	Stop E	ate	Reason	
						1	
Substance abuse				Tobacc	LIEO		
Substance abuse	Dete	Det		Tobacco		D. C.	D. C.
Substance abuse assessed	<u>Date</u>	Date		Tobacco asses		<u>Date</u>	<u>Date</u>
	<u>Date</u>	Date					<u>Date</u>

PATIENT	EN	CC	IU(NTER	RFC	R

LABS

CD4 count

(percentage)

NADIR CD4

Viral Load

Resistance Testing

V

RESULT

Shenandoah Valley Medical Systems

Physician

Patient #

DATE

RESULT

INVESTIGATION

If Hep C + then PCR & Genotype

Mammogram (if >=40 yr old)

GC/Chlamydia (yearly)

Syphilis (yearly)

Toxoplasma IgG

Hep B sAg / sAb

Hep C Ab

PPD

Hep B Core Ab / IgM

Hep A Total Ab / IgM

Pap Smear (yearly)

Nutrition Screening

Living Will / MPOA

Dental Exam

HIV Education

CMV

Eye Exam (if CD4 <50)

Lipid Screening (yearly)

Mental Health Screening Partnership for Health int.

Prevention and Wellness Patient Assessment Form

Established

Risk: | IDU | MSM | Heterosexual Contact | Perinatal | Hemophilia/Coag Dis/Transf | Undetermined

Date of Diagnosis: __ / __ / __ Year likely infected _____

DATE

Ols/ Neoplasms/ Co		VACCINA	ATIONS	<u>Da</u>	<u>te</u>		
1	7			Pneumococcal	(q 5 years)		
2	8			Influenza (yearly	y)		
3	9			Hepatitis A #1			
4	10			Hepatitis A #2			
5	11			Hepatitis B #1			
6	12			Hepatitis B #2			
Allergies / Adverse I	Rx prior	to AR	T	Hepatitis B #3			
				Tetanus/Diphthe	eria (q 10yr)		
				H1N1			
			<u>Start</u>				
042 Medications	Dose/	Freq	<u>Date</u>	Stop D	ate	Reason	
		•			<u> </u>		
Dharmany Assass	mont	Data	Doto	Data	Doto	Commente	
Pharmacy Assess		<u>Date</u>	<u>Date</u>	<u>Date</u>	<u>Date</u>	Comments	
a. Adherence Couns							
b. Quantitative Asso	essment						
Madiaationa for						<u> </u>	
Medications for	D. "	-	044-0-4	04 5	4 -	D	
<u>Prophylaxis</u>	Dose/	<u>-req</u>	Start Date	Stop D	<u>ate</u>	Reason	
Cubatanas abusa				Tabaass			
Substance abuse				Tobacco			
<u>assessed</u>	<u>Date</u>	<u>Date</u>		assess	<u>sed</u>	<u>Date</u>	<u>Date</u>


Additional Notes:

					Physician	SM 2006
Date of Diagnosis:		187	Year lik	ely infected Early 86's	Establishe	200 Cp
Risk: oldu omsm y	Heterosex	ual Co	ntact oPe	rinatal Trans Hemoph	illia/Coag Di	isorder/Transfusion
LABS	DATE	RE	SULT	INVESTIGATION	DATE	RESULT
Table Control	1100	247		Syphilis (yearly)	318/10	NR
004	5105	3.24	3.07%	GC/Chiamydia (yearly)	SIEILS	11.15
CD4 count	5109	352	30%	Toxoplasma lgG	318/10	4 0.90
(percentage)	12109	28 G	21 70	Hegt B sAg / sAb	10/11/06	010
	3110	28.6 230	2.1%	Hep B Core Ab / IgM	1011106	(E) (E)
CONTRACTOR OF CO.				Hep C Ab	rollion	(3)
NADIR CD4				If Hep C + then PCR & Genoty		
	DIACT	317		Hep A Total Ab / IgM	10/1/10/6	0,10
	1109	31	28	PPD	311100	Ø mm
appropriate.	5105	- 4	48	Pap Green (yearly)		
Viral Load	2019	7.7	48	Mammogram (if >=40 yr old)- Eye Exam (if CD4 <50)		
	3110	40	80	Dental Exam		Referen
	911.0		folial -	Lipid Screening (yearly)	3hhi to	190,45,874
Resistance Testing				Nutrition Screening	5	
				Mental Health Screening)	
0	21	10.10		Partnership for Health Int.	(3/8/	1010
Genotype	217	1010		HIV Education	7	
No 1				Prevention and Wellness	1	
140 1	N. TO'L	1016	2	Patient Assessment Form	1011106	No state of
				CMV WIII / MPGA	TOTTOO	Harriout
Opportunistic Infects	ons/ Neon	lasms/		UM P	1918/10	3.7B(E)
Comorbids				VACCINATIONS	De	ste
Herpes Simple	400			The state of the s		109
the second second	ALC: NO.			Printersococcos on 5 years)		1.1.34
				Priesmococcal (q 5 years) Influenza (yearly)	-	
1	2			Influence (yearly) Hepatitis A #1	12.13	109
1	10			Beforence (yearly) Hepatitis A #1 Hepatitis A #2	12.13	104
1	10 10 11			influence (yearly) Hepatitis A #1 Hepatitis A #2 Hepatitis B #1	315	107
Allosoine / Advers - P	12	ADT		influence (yearly) Hepatitis A #1 Hepatitis A #2 Hepatitis B #1 Hepatitis B #2	121 to 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10 18 10	107
Allergies / Adverse R	x to prior	ART the	ecapy	Infraeron (yearly) Hepatitis A #2 Hepatitis B #2 Hepatitis B #2 Hepatitis B #2 Hepatitis B #3	121 15 31 5 10 18 31 5 10 17	104 107 107 107 107
Allergies / Adverse R	x to prior	ART th	есару	influence (yearly) Hepatitis A #1 Hepatitis B #1 Hepatitis B #2 Hepatitis B #2 Hepatitis B #3 Tetanus/Diphtheria (g 10yt)	121 15 31 5 10 18 31 5 5112 10 13	104 01 01 107 107 3107 1 2004
Allergies / Adverse R Sultra, Rug	x to prior	ART th	erapy	Infraeron (yearly) Hepatitis A #2 Hepatitis B #2 Hepatitis B #2 Hepatitis B #2 Hepatitis B #3	121 15 31 5 10 18 31 5 5112 10 13	104 107 107 107 107
Sulta, Aug	tx to prior	v.	Start	Influence (yearly) Hepatitis A #1 Hepatitis B #2 Hepatitis B #2 Hepatitis B #2 Hepatitis B #3 Tetanus/Diphtheria (g 10yt) H1N1	12.13 8.15 8.15 8.15 5.11 10.11 10.11	104 01 01 107 107 3107 1 2004
Sulfa, Aug	x to prior	Freq	- 17/21	influence (yearly) Hepatitis A #1 Hepatitis B #1 Hepatitis B #2 Hepatitis B #2 Hepatitis B #3 Tetanus/Diphtheria (g 10yt)	121 15 31 5 10 18 31 5 5112 10 13	104 01 01 107 107 3107 1 2004
O42 Medications	Dose/	Freq	Start Date	infrance (yearly) Hepatitis A #1 Hepatitis B #2 Hepatitis B #1 Hepatitis B #2 Hepatitis B #3 Tetanus/Diphtheria (g 10)(f) H1N1 Stop Date	12.13 8.15 8.15 8.15 5.11 10.11 10.11	104 01 01 107 107 3107 1 2004
942 Medications Lexisla 70000 Trustada actio	Dosei	Freq 61b	Start	informan (yearly) Hepatitis A #1 Hepatitis B #2 Hepatitis B #1 Hepatitis B #2 Hepatitis B #3 Tetanus/Diphetheria (g 10)(f) H1N1 Stop Date	12.13 8.15 8.15 8.15 5.11 10.11 10.11	104 01 01 107 107 3107 1 2004
O42 Medications	Dosei	Freq 61b	Start Date	informan (yearly) Hepatitis A #1 Hepatitis B #2 Hepatitis B #1 Hepatitis B #2 Hepatitis B #3 Tetanus/Diphetheria (g 10)(f) H1N1 Stop Date	12.13 8.15 8.15 8.15 5.11 10.11 10.11	104 01 01 107 107 3107 1 2004
942 Medications Lexisla 70000 Trustada actio	Dosei	Freq 61b	Start Date	informan (yearly) Hepatitis A #1 Hepatitis B #2 Hepatitis B #1 Hepatitis B #2 Hepatitis B #3 Tetanus/Diphetheria (g 10)(f) H1N1 Stop Date	12.13 8.15 8.15 8.15 5.11 10.11 10.11	104 01 01 107 107 3107 1 2004
942 Medications Ltx13/0. 70000 Tyr13/0.da, actio R11000017 100	Doser Links	Freq 61b	Start Date	informan (yearly) Hepatitis A #1 Hepatitis B #2 Hepatitis B #1 Hepatitis B #2 Hepatitis B #3 Tetanus/Diphetheria (g 10)(f) H1N1 Stop Date	12.13 8.15 8.15 8.15 5.11 10.11 10.11	104 01 01 101 101 101 1107 17004 1131 04
942 Medications Lexive 700 Truvada, acts Ritorouse 100 Pharmacy Assess a. Adherence Couns	Doser Link Link Link Link Link Link Link Link	Freq 61b 61b 61b	Start Date 2	infraeron (yearly) Hepatitis A #1 Hepatitis A #2 Hepatitis B #2 Hepatitis B #2 Hepatitis B #3 Tetanua/Ophtheria (q. 10yt) H1N1 Stop Date	12.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3	104 01 01 101 101 101 1107 17004 1131 04
942 Medications Lexive 700 Truvada, acts Ritorouse 100 Pharmacy Assess a. Adherence Couns	Doser Link Link Link Link Link Link Link Link	Freq 61b 61b 61b	Start Date (81200	infraeron (yearly) Hepatitis A #1 Hepatitis A #2 Hepatitis B #2 Hepatitis B #2 Hepatitis B #3 Tetanua/Ophtheria (q. 10yt) H1N1 Stop Date	12.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3	104 01 01 101 101 101 1107 17004 1131 04
942 Medications Lexive 700 Truvada, acts Ritorouse 100 Pharmacy Assess a. Adherence Couns	Doser Link Link Link Link Link Link Link Link	Freq 61b 61b 61b 61b	Start Date 81200	infraeron (yearly) Hepatitis A #1 Hepatitis A #2 Hepatitis B #2 Hepatitis B #2 Hepatitis B #3 Tetanua/Ophtheria (q. 10yt) H1N1 Stop Date	12.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3	104 01 01 101 101 101 1107 17004 1131 04
942 Medications Lexiste 700 Pharmacy Assess a. Adherence Couns b. Quantitative Asses	Dosei	Freq 61b 61b 61b 61b 61b 61b 61b 61b	Start Date 2 81200 Date 3110	Influence (yearly) Hepatitis A #1 Hepatitis B #1 Hepatitis B #2 Zetanus/Diphetheria (g. 10yt) H1N1 Stop Date Date Date Date Date	12.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3	104 01 01 101 101 101 1107 17004 1131 04
942 Medications Legano 700 m Transit da actio Ratherine Couns b. Quantitative Assess Medications for Prophylaxis	Doser Link Link Link Link Link Link Link Link	Freq 61b 61b 61b 61b 61b 61b 61b 61b	Start Date Date Date 31.10 1002	Influence (yearly) Hepatitis A #1 Hepatitis B #2 One Date Date Date Stop Date	Reason Reason	109 107 107 107 107 1 2004 113 09
942 Medications Lexiste 700 Pharmacy Assess a. Adherence Couns b. Quantitative Asses	Dosei	Freq 61b 61b 61b 61b 61b 61b 61b 61b	Start Date 2 81200 Date 3110	Influence (yearly) Hepatitis A #1 Hepatitis B #2 One Date Date Date Stop Date	12.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3.1 (3	109 107 107 107 107 1 2004 113 09
942 Medications Legano 700 m Transit da actio Ratherine Couns b. Quantitative Assess Medications for Prophylaxis	Dosei	Freq 61b 61b 61b 61b 61b 61b 61b 61b	Start Date Date Date 31.10 1002	Influence (yearly) Hepatitis A #1 Hepatitis B #2 One Date Date Date Stop Date	Reason Reason	109 107 107 107 107 1 2004 113 09
942 Medications Legisle 700 m Transida active Rithmosty 100 Pharmacy Assess a. Adherence Couns b. Quantitative Asse Medications for Prophylaxis Acycloxic	Dose/	Freq 610 625 810 Date 1210 1005	Start Date Date Date 31.10 1002	Influence (yearly) Hepatitis A #1 Hepatitis B #1 Hepatitis B #2 He	Reason Har pe	109 101 101 107 107 1200 113109
942 Medications Lexiste 700m Transit of a settle Refrence Cours B. Quantitative Assess Medications for Prophylaxis	Dose/	Freq 61b 61b 61b 61b 61b 61b 61b 61b	Start Date Date Date 31.10 1002	Influence (yearly) Hepatitis A #1 Hepatitis B #2 One Date Date Date Stop Date	Reason Reason	109 107 107 107 107 1 2004 113 09

DATE	RES	ULT		
1109 5109 8109 1210 0118	247 324 352 286 230	30% 30% 21%)	
5/09 5/09 12/09 3/10	318 20 23 401	18 18 30 30		
Dose/Freq 1 Hab BID 7 1 tab BID 7	Start Date	Stop I	Date	Reason
	1109 5109 8109 17109 3110 1109 5109 12109 3110 Dose/Freg 1 Hob 810 2	1109 247 5109 324 8109 352 12109 286 3110 230 1109 230 1109 230 1109 230 5109 230 5109 230 5109 230 5109 230 Start Date 1108 810 2812006	1109 247 229 5109 324 3096 8109 352 3096 12109 286 2196 3110 230 2146 5109 49 12109 2330 12109 2330 3110 4080 Start Date Stop 1 1 140 810 7 1 140 810 7 1 140 810 7	1109 247 22% 5 09 3 2 30% 30% 12 09 28 6 21% 21% 3 10 230 21% 230 21% 3 10 230 21% 3 10 230 21% 3 10 4 2 3 3 0 3 10 4 0 8 0 3 10 4 0 8 0 0 1 10 10 10 10

As a provider what would you do...

- Change the Regimen
- Recommend Mental Health and Adherence Counseling
- 3. Stop All Medication
- Call Ghost Busters




Pharmacy Assessm Adherence Counsel Quantitative Assess	ling	Date 12 09 100%	3 10 100%	<u>Date</u> <u>Date</u>	Comments		
Medications for Prophylaxis	Dose/Freq		Start Date	Stop Date	Reason		
Sub abuse assessed (1) ETOH	Date 3 2010	Date		Tobacco use	<u>Date</u> 312010	<u>Date</u>	

Quality Management Indicators

- **■**Patients on ART
- ■Undetectable VL patients on ART
- ■CD4 <200
- Labs / annual screenings
- Immunizations



Quality Management



You Can DO IT!!



Education



Role of the West Virginia Local Performance Site of the PA/MA AETC

- Monthly Patient Care Teleconference Call
- **■CME Credit**
- Expertise of Providers
- Programs Provided




Monthly Patient Care Teleconference

- Fourth Tuesday of every month
 - Patients' Encounter forms faxed
 - Encounter forms copied and provided to ID physician
 - At least twice a year an educator from the WVLPS travels and participates in the call at the Shenandoah Site



What is a PIF

- Pretty Intelligent Friend
- Participation Information Form
- Please Include Food



Monthly Patient Care Teleconference

- Participant Information forms
 - Are pre-filled for each participant
 - Collected by the nurse after the call
 - Mailed to the Local Performance Site




Participants

- WVLPS of the PA/MA AETC
 - ID physician (represents both AETC and Part C)
 - Nurse Educators
- Ryan White Part C
 - ID physician
 - Nurse



What do you think we did to encourage providers to attend the patient care teleconference call

- 1. Food
- 2. Gift Cards
- 3. Continuing Education Credit
 - Tickets to Redskin's Game



Continuing Education Credit

- 1 hour AMA PRA Category 1 credit
- ■1.2 hours of nursing credit
- 1 hour of social worker credit



Expertise of providers

- Patient encounter forms kept since inception to monitor progression of patient care
- Quality performance measures have improved
- According to the ID physicians, questions presented via the MARS line have become more complex
- Provider invited speaker at the annual West Virginia Ryan White All Parts HIV conference



Programming

- Numerous HIV/AIDS programs have been provided in the area
- HIV/AIDS programs have been conducted at the Shenandoah site
- At least one teaching point is presented and discussed at each patient care teleconference call



Summary

- Quality HIV care can be provided by Community Health Centers
- Patients receive care closer to their residence
- This has been a very successful partnership between Ryan White Part C, the Community Health Center and the AETC as well as Ryan White Parts A and B, and local CBOs
- This is an economical alternative to the traditional model

